Phase 2 Leukaemia Trial, Recruiting NCT06557161 Sponsor: The First Affiliated Hospital of Zhengzhou University Condition: Leukaemia
Back to Leukaemia

Phase 2 Leukaemia Trial, Recruiting

NCT06557161
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are willing to voluntarily sign a written consent form agreeing to take part in the study.
  • People who are male or female, aged between 18 and 65 years old.
  • People who have been diagnosed with acute lymphoblastic leukemia (a type of blood cancer) according to World Health Organization standards.
  • People whose leukemia has gone into full remission (meaning no signs of active leukemia in the blood) before the transplant takes place.
  • People who have a matching brother or sister available to donate stem cells, and who consent to receiving a stem cell transplant from that sibling donor.
  • People who are generally able to care for themselves and carry out normal daily activities, as measured by a standard health performance scale (score of 70 or higher out of 100).
  • People whose heart, liver, kidney, and lung function all fall within acceptable ranges as determined by specific medical tests (confirm exact values with the trial site).
  • Women who could become pregnant must have a negative pregnancy test at the start of the study and must agree to use effective contraception for at least one year after the transplant.
  • Male participants whose partners could become pregnant must agree to use effective barrier contraception and not donate sperm for at least one year after the transplant.

Who may not be able to join:

  • People whose leukemia has not gone into full remission before the planned transplant.
  • People who have chosen a stem cell donor who is not a matched sibling.
  • People with serious heart, liver, kidney, or lung disease that would make it unsafe to go through the pre-transplant treatment process.
  • People who have an active infection that is not responding to treatment, or other serious life-threatening complications.
  • People who have a history of another type of cancer, a psychiatric disorder, or HIV infection.
  • People who are unwilling to sign the consent form, unable to attend the required follow-up visits, or do not agree to allow their data to be used to support future research and medical practice.
  • People whom the trial investigators consider unsuitable for any other reason.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +86037166862278

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
The First Affiliated Hospital of Zhengzhou University
Registry
ClinicalTrials.gov
Start date
1 March 2025
Est. completion
31 August 2029

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Relapse-free survival (RFS); acute Graft Versus Host Disease (aGVHD); Overall Survival (OS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov